Research tools
Colonoscopy articles covering diagnosis, disease monitoring, cancer surveillance, mucosal healing, and IBD research. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
39 articles
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...
AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...
The study suggests a probiotic strain (Lactobacillus plantarum) reduced inflammation and prolonged remission in multiple mouse models of Crohn’s-like disease, indicating microbiome-based approaches might be promising to...
The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...
This trial tests a new oral drug, AC-101, for moderate-to-severe ulcerative colitis and may expand future treatment options if it proves effective and safe. The study targets patients who have failed or could not...
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
Preneoplastic (adenomatous and serrated) polyps can be precursors to colorectal cancer, so knowing how common they are and what raises risk may affect surveillance planning for people with ulcerative colitis.
Better automated segmentation of inflammatory lesions could make colonoscopy assessments more objective and consistent, which matters for monitoring IBD activity and for clinical trials that rely on endoscopic endpoints.
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
People with moderate-to-severe Crohn’s disease may be interested because the study explores a new, repurposed drug (vorinostat) that targets epigenetic and immune pathways and includes a plan to move responding...
This trial tests a new oral drug (Alpha-0261) for moderate-to-severe ulcerative colitis and could matter to people who haven’t responded to standard medicines. Early-phase studies mainly assess safety but also collect...
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Colonoscopy. The original article is from Digestive and Liver Disease.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
A validated pre-endoscopic model could help estimate UC disease extent before colonoscopy, aiding clinical triage and planning without replacing endoscopy.
LCH can present like perianal Crohn's disease and may be missed if biopsies and molecular testing are not performed. Correct diagnosis changes treatment and prompts systemic staging for other malignancies.
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...
A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
The study suggests a blood cytokine (CXCL9) could help noninvasively detect intestinal inflammation in Crohn’s disease, which might one day reduce reliance on colonoscopy for monitoring disease activity.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...
Based on the title and source metadata, this appears to be a clinical study related to Irritable bowel syndrome, Upadacitinib, and JAK inhibitor. The original article is from msn.com.
This reports a company moving a MAP-targeted antibiotic-like therapy (RHB-204, related to RHB-104) into a Phase 2 trial for Crohn’s disease with mucosal healing and MAP eradication as key endpoints—topics that could...
People with Crohn’s disease who have an ileostomy have limited noninvasive ways to monitor small-bowel inflammation. This study suggests measuring fecal calprotectin from ileostomy output could help detect postoperative...
